SUBSCRIBE
SUBSCRIBE
Matthew Winton stands with his arms crossed looking at the camera

Matthew Winton

Matthew Winton

Matthew Winton, Ph.D., is chief operating officer at Inozyme Pharma, a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases linked to the PPi-Adenosine Pathway.

Biopharmaceutical executives on the steps of the U.S. Capitol building in Washington, DC
Opinion
Congress Must Reauthorize FDA Program for Pediatric Rare Diseases
Why I advocated on Capitol Hill this month for the renewal of the FDA’s Priority Review Voucher program
July 15, 2024
 · 
6 min read
 · 
Matthew Winton